NASDAQ: KPTI
Karyopharm Therapeutics Inc Stock Ownership - Who owns Karyopharm Therapeutics?

Insider buying vs selling

Have Karyopharm Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Kristin AbateCAO2026-09-0119$2.02
$38.38Sell
Stuart PoultonEVP;CXO2026-07-28189$7.10
$1.34kSell
Reshma RangwalaEVP Chief Medical Officer2026-05-14408$9.50
$3.88kSell
Kristin AbateChief Accounting Officer2026-05-1453$9.50
$503.50Sell
Sohanya Roshan ChengEVP Chief Commercial Officer2026-05-14324$9.50
$3.08kSell
Michael ManoEVP CLOSecretary2026-05-14266$9.50
$2.53kSell
Richard A. PaulsonPresident and CEO2026-05-142,203$9.50
$20.93kSell
Stuart PoultonEVP Chief Development Officer2026-05-14403$9.50
$3.83kSell
Reshma RangwalaEVP Chief Medical Officer2026-04-21449$8.94
$4.01kSell
Michael ManoEVP CLOSecretary2026-03-023,526$9.41
$33.18kSell

1 of 2

KPTI insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KPTI insiders and whales buy or sell their stock.

KPTI Shareholders

What type of owners hold Karyopharm Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Chione Ltd71.68%16,258,079$26.01MInsider
Plio Ltd27.94%6,336,946$10.14MInsider
Marcin Czernik26.15%5,930,939$9.49MInsider
Deepika Pakianathan10.14%2,298,851$3.68MInsider
Sharon Shacham7.37%1,671,888$2.68MInsider
Michael Kauffman7.11%1,611,888$2.58MInsider
Michael Mason1.72%391,054$625.69kInsider
Richard A. Paulson1.19%269,747$431.60kInsider
Ran Frenkel0.74%168,290$269.26kInsider
Jatin Shah0.57%129,450$207.12kInsider

1 of 3

KPTI vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KPTI0.06%99.94%Net SellingNet Selling
CELU0.00%100.00%Net Selling
FLNA0.03%73.68%Net Buying
CNTX0.07%1.43%
CRVO0.00%100.00%Net Buying

Karyopharm Therapeutics Stock Ownership FAQ

Who owns Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ: KPTI) is owned by 0.09% institutional shareholders, 158.30% Karyopharm Therapeutics insiders, and 0.00% retail investors. Chione Ltd is the largest individual Karyopharm Therapeutics shareholder, owning 16.26M shares representing 71.68% of the company. Chione Ltd's Karyopharm Therapeutics shares are currently valued at $25.04M.

If you're new to stock investing, here's how to buy Karyopharm Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.